Press Release

NeuroStar® Advanced Therapy and Transformations TMS Expanding Partnership to Increase Patient Access to Depression Treatment

November 15, 2018

NeuroStar Advanced Therapy ogo

FOR IMMEDIATE RELEASE
NeuroStar® Advanced Therapy, the established leader in transcranial magnetic stimulation (TMS), announced an expanded partnership with GRW Health, the head company of Harmony and Transformations TMS. Transformations TMS will offer NeuroStar Advanced Therapy at six new locations across Pennsylvania and West Virginia. Harmony, a clinic dedicated to the treatment of mental illness and restoration of mental well-being, has offered NeuroStar at three of its locations since December 2017. With this most recent expansion, GRW Health will now have 11 NeuroStar TMS systems installed across their nine locations.

NeuroStar Advanced Therapy uses magnetic pulses to awaken areas of the brain that are underactive in depression. With its advanced technology, NeuroStar Advanced Therapy offers doctors real-time feedback and delivers enhanced care with its precise and accurate targeting, providing reliable and consistent treatment. In an open-label clinical trial, 58% of patients significantly responded to treatment, and 37% achieved complete remission of their depression symptoms with NeuroStar Advanced Therapy TMS. Among people followed for 12 months after acute treatment, 68% retained their response and were considered in remission for the duration of a full year.

“I am thrilled to be expanding our relationship with GRW Health to increase patient access to this transformative treatment and help more people find relief from their depression,” said Chris Thatcher, President and CEO of Neuronetics, Inc. “GRW Health’s increased investment in NeuroStar TMS demonstrates their commitment to the proven efficacy of this non-drug treatment option and its ability to transform lives.”

In 2018, Harmony TMS has already treated more than 75 patients and expects to see more than 100 patients across the Transformations TMS locations by the end of the year. 

“We strive for the highest quality of psychiatric care and we’re excited to offer NeuroStar Advanced Therapy at more of our locations across Pennsylvania and West Virginia,” said Dr. Ryan Wakim, founder and president of GRW Health. “We have a committed team looking to help alleviate our patients’ depression symptoms as much as possible, and we know NeuroStar works and provides the best possible chance at long-term remission from depression. In fact, I’ve been so impressed by the results I’ve seen,  I’ve even recommended NeuroStar to my own family members struggling with depression. ”

Since receiving FDA clearance in 2008 as a safe and effective treatment for adult patients with MDD, NeuroStar Advanced Therapy has become a game-changer in the treatment of depression and offers hope to the 5.5 million adults in the U.S. treated for depression who do not achieve remission with antidepressant medication. With widespread insurance coverage by most commercial and government health plans including Medicare and Tricare, the non-drug therapy is available by prescription and typically administered daily in a doctor's office for four to six weeks, with treatment sessions performed in as little as just under 19 minutes.* Unlike electroconvulsive therapy (ECT), NeuroStar Advanced Therapy is non-invasive and allows patients to resume daily activities immediately following treatment sessions. It is also free from systemic side effects often associated with antidepressant medications.

side effects of TMS diagram
NeuroStar Advanced Therapy (TMS) is safe and easy to tolerate. Because it is not a depression drug, NeuroStar TMS Therapy does not have the same side effects that are associated with traditional antidepressant medications.

Transformations TMS locations will now include Denver, CO; Fox Chapel, PA; McMurray, PA; Monroeville, PA; Mt. Lebanon, PA; Robinson, PA; Wexford, PA; Weirton, WV and Wheeling, WV. 

Visit www.NeuroStar.com for more information about NeuroStar Advanced Therapy.

About NeuroStar® Advanced Therapy

NeuroStar® Advanced Therapy is the established leader in transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation. NeuroStar Advanced Therapy is the #1 TMS choice of doctors for patients with MDD, and is widely available across the United States.

diagram of brain areas with NeuroStar tms device
NeuroStar uses transcranial magnetic stimulation (TMS) to target key areas of the brain that are underactive in people with depression.

NeuroStar is widely reimbursed by most commercial and government health plans, including Medicare and Tricare. In addition, there are programs in place, such as NeuroStar Reimbursement Support, to help patients and providers obtain coverage and reimbursement for NeuroStar Advanced Therapy.

NeuroStar is indicated for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were four times more likely to achieve remission compared to patients receiving sham treatment (P = 0.0173; odds ratio = 4.05). The most common side effect is pain or discomfort at or near the treatment site, which usually resolves within one week. It is contraindicated in people with non-removable conductive metal in or near the head. 

chart of duration of NeuroStar TMS therapy
Only NeuroStar Advanced Therapy (TMS) has durability over 12 months. (Source: Neurostar)

NeuroStar® is a registered trademark of Neuronetics, Inc. For more information and full safety and prescribing information, visit www.neurostar.com.

Media Contact:

Meagan Dominick

Office: 610-455-2779

Mobile: 773-369-4255

mdominick@vaultcommunications.com

Notes, Citations, and Further Reading:

 Carpenter LL, et al.  Depress Anxiety, (2012)

 Dunner DL, et al. J Clin Psychiatry, (2014).

* Treatment time may vary depending on doctor's recommendation.

 Kessler RC, et al. JAMA, (2003) 

 https://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml, accessed 1/16/2018

 Gaynes BN et al., Cleveland Clinic Journal of Medicine 2008;75(1):57-66  

 Janicak PG, et al. J Clin Psychiatry, (2008)

 George MS, et al. Arch Gen Psychiatry, (2010)

...

Recent Posts